Abstract:ID 131403 Poster Board 569 Chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are highly homologous G-protein coupled receptors on the surface of select immune cells with distinct functions and endogenous agonists but with select shared antagonists. These chemokine receptors are promising targets for small molecule therapeutics in the treatment of various cancers and autoimmune diseases, despite only one currently approved therapeutic for CCR5. Rational design of future therapeutics relies on a structural understanding of the determinants of antagonist selectivity as high affinity targeting of only one receptor is often desired. Further complicating therapeutic development, antagonists of human CCR2 (hCCR2) are often inactive to mouse CCR2 (mCCR2). Here, through rationally-guided gain-of-function mutagenesis, we characterized the molecular determinants of CCR2/CCR5 and human/mouse antagonist selectivity. Binding poses for a panel of selective and dual-specific antagonists were generated through molecular docking. Using these poses, we hypothesized that a single bulky residue in TM2 of hCCR5 (Y892.63) and mCCR2 (Y1142.63) dictates selectivity by obstructing binding of the minor pocket-targeting orthosteric antagonists with large substituents. By contrast, the corresponding S1012.63 of hCCR2 is permissive to the binding of such antagonists because it allows them to occupy space otherwise filled by tyrosine. To validate this hypothesis, we introduced a Y892.63S mutation into human CCR5 and tested the ability of a previously CCR2-selective antagonist cherney08a_22 to inhibit chemokine-induced suppression of forskolin-stimulated cAMP in HeLa cells expressing the mutant. Intracellular cAMP levels were measured with the BRET-based CAMYEL reporter. These experiments confirmed that indeed the CCR5(Y892.63S) mutant became sensitive to cherney08a_22 . We also demonstrated how the same residue could impart selectivity against human CCR5 and mouse CCR2 to antagonists with a medium-size (acetamide) substituent. An alternative hypothesis was assessed for CCR2-selective antagonists predicted to bind towards TM5 and the major pocket. Selectivity for these hCCR2 antagonists was suspected to be conveyed by residues F1093.33, S18045.52, or I1985.42 of human CCR5, which are distinct from their CCR2 counterparts. However, the introduction of CCR2-mimicking F1093.33H and S18045.52P mutations in hCCR5 was not sufficient to produce sensitivity to major pocket-targeting CCR2-selective antagonist PF-4136309 . We therefore concluded that its selectivity mechanism is due to the hCCR2 residue R2065.42 which is I1985.42 in hCCR5. Our findings provide a better framework for the rational development of selective and dual-affinity antagonists for CCR2 and CCR5 to overcome past deficiencies in design of potent and selective inhibitors.

Selection of CC chemokine receptor 5-binding peptide from a phage display peptide library.

Chemokine Receptor Ccr5 Functionally Couples to Inhibitory G Proteins and Undergoes Desensitization

Establishment of A New Cell Line for High-Throughput Evaluation of Chemokine Ccr5 Receptor Antagonists

Novel peptide screened from a phage display library antagonizes the activity of CC chemokine receptor 9.

Establishment and characterization of CHO cell line stably expressing human CCR5 gene

Advances of CCR5 antagonists: From small molecules to macromolecules

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Induced recovery of defective membrane expression of a CC chemokine receptor 5 mutant by phytohemagglutinin

Isolation and Structure of Antagonists of Chemokine Receptor (CCR5).

A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine Vmip-Ii

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

The Membrane-Proximal Region of C–C Chemokine Receptor Type 5 Participates in the Infection of HIV-1

High Affinity CXCR4 Inhibitors Generated by Linking Low Affinity Peptides.

A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody.

A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist

Construction, Purification, and Immunogenicity of Recombinant Cystein-Cystein Type Chemokine Receptor 5 Vaccine.

Small Molecular CCR5 Antagonists As HIV Inhibitors:A Review of Recent Research

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5